Q-omics provides the consensus-scored MIR4648 profile across patient tissues and cancer cell-line models. MIR4648 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MIR4648 is differentially expressed in 4, with the highest sampling consensus in STAD. Additionally, MIR4648 RNA expression shows 11,043 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, STAD, and THYM as cancer lineages where MIR4648 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4648 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4648 survival associations across molecular data types. MIR4648 RNA expression shows survival associations in the most cancer types (19). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4648 RNA expression–survival associations across cancer types. High MIR4648 expression shows unfavorable associations in DLBC, MESO and PCPG, but favorable associations in UCS, LUAD and BLCA. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .019). Together, the overview and detailed table identify UCS as the clearest survival context for MIR4648 RNA expression.
This table summarizes MIR4648 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in STAD for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4648. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4648 shows lower tumor expression in KICH and higher tumor expression in STAD, COAD and LUAD. The STAD box plot shows higher MIR4648 RNA expression in tumor versus normal tissue (log2 FC = +0.664, t-test p < 0.001).
This table shows molecular features associated with MIR4648 in patient tissues and cancer cell lines. In patient samples, MIR4648 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
